{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T09:02:38Z","timestamp":1785229358235,"version":"3.55.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T00:00:00Z","timestamp":1779926400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["New Microbes and New Infections"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.nmni.2026.101776","type":"journal-article","created":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:02:52Z","timestamp":1780038172000},"page":"101776","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches"],"prefix":"10.1016","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9050-9016","authenticated-orcid":false,"given":"Sanaz","family":"Ahmadi Ghezeldasht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3827-515X","authenticated-orcid":false,"given":"Raheleh","family":"Miri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Khosrow","family":"Shamsian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8408-4664","authenticated-orcid":false,"given":"Arman","family":"Mosavat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6814-5992","authenticated-orcid":false,"given":"Seyed Abdolrahim","family":"Rezaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.nmni.2026.101776_bib1","doi-asserted-by":"crossref","first-page":"7415","DOI":"10.1073\/pnas.77.12.7415","article-title":"Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma","volume":"77","author":"Poiesz","year":"1980","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.nmni.2026.101776_bib2","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1073\/pnas.79.6.2031","article-title":"Isolation and characterization of retrovirus from cell lines of human adult T-cell leukemia and its implication in the disease","volume":"79","author":"Yoshida","year":"1982","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"8452","key":"10.1016\/j.nmni.2026.101776_bib3","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S0140-6736(85)92734-5","article-title":"Antibodies to human T-lymphotropic virus type-I in patients with tropical spastic paraparesis","volume":"2","author":"Gessain","year":"1985","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.nmni.2026.101776_bib4","doi-asserted-by":"crossref","first-page":"1862","DOI":"10.1007\/s12010-022-04259-y","article-title":"Development of a novel HTLV-1 protease: human Fcgamma1 recombinant fusion molecule in the CHO eukaryotic expression system","volume":"195","author":"Ahmadi","year":"2023","journal-title":"Appl Biochem Biotechnol"},{"issue":"3","key":"10.1016\/j.nmni.2026.101776_bib5","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1021\/acschembio.0c00975","article-title":"Inhibiting HTLV-1 protease: a viable antiviral target","volume":"16","author":"Lockbaum","year":"2021","journal-title":"ACS Chem Biol"},{"issue":"1","key":"10.1016\/j.nmni.2026.101776_bib6","doi-asserted-by":"crossref","first-page":"152","DOI":"10.3390\/v14010152","article-title":"HIV-1 and HTLV-1 transmission modes: mechanisms and importance for virus spread","volume":"14","author":"Kalinichenko","year":"2022","journal-title":"Viruses"},{"issue":"14","key":"10.1016\/j.nmni.2026.101776_bib7","doi-asserted-by":"crossref","first-page":"6266","DOI":"10.1021\/jm500402c","article-title":"Structural basis for HTLV-1 protease inhibition by the HIV-1 protease inhibitor indinavir","volume":"57","author":"Kuhnert","year":"2014","journal-title":"J Med Chem"},{"issue":"7","key":"10.1016\/j.nmni.2026.101776_bib8","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263200","article-title":"Comparative study of the unbinding process of some HTLV-1 protease inhibitors using unbiased molecular dynamics simulations","volume":"17","author":"Tiyoula","year":"2022","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.nmni.2026.101776_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0257916","article-title":"Comparative analysis of the unbinding pathways of antiviral drug indinavir from HIV and HTLV1 proteases by supervised molecular dynamics simulation","volume":"16","author":"Sohraby","year":"2021","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.nmni.2026.101776_bib10","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1046\/j.1365-2613.2001.00191.x","article-title":"Molecular biology and pathogenesis of the human T-cell leukaemia\/lymphotropic virus Type-1 (HTLV-1)","volume":"82","author":"Johnson","year":"2001","journal-title":"Int J Exp Pathol"},{"issue":"1","key":"10.1016\/j.nmni.2026.101776_bib11","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12977-020-00517-1","article-title":"Functional properties and sequence variation of HTLV-1 p13","volume":"17","author":"Omsland","year":"2020","journal-title":"Retrovirology"},{"key":"10.1016\/j.nmni.2026.101776_bib12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1146\/annurev-immunol-042617-053222","article-title":"Human T cell leukemia virus type 1: persistence and pathogenesis","volume":"36","author":"Bangham","year":"2018","journal-title":"Annu Rev Immunol"},{"issue":"26","key":"10.1016\/j.nmni.2026.101776_bib13","doi-asserted-by":"crossref","first-page":"27148","DOI":"10.1074\/jbc.M401868200","article-title":"Narrow substrate specificity and sensitivity toward ligand-binding site mutations of human T-cell leukemia virus type 1 protease","volume":"279","author":"Kadas","year":"2004","journal-title":"J Biol Chem"},{"issue":"6207","key":"10.1016\/j.nmni.2026.101776_bib14","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/337576a0","article-title":"Crystal structure of a retroviral protease proves relationship to aspartic protease family","volume":"337","author":"Miller","year":"1989","journal-title":"Nature"},{"key":"10.1016\/j.nmni.2026.101776_bib15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.compbiolchem.2015.04.002","article-title":"Characterizing the protonation states of the catalytic residues in Apo and substrate-bound human T-cell leukemia virus type 1 protease","volume":"56","author":"Ma","year":"2015","journal-title":"Comput Biol Chem"},{"issue":"2","key":"10.1016\/j.nmni.2026.101776_bib16","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3390\/life11020127","article-title":"Biochemical characterization, specificity and inhibition studies of HTLV-1, HTLV-2, and HTLV-3 proteases","volume":"11","author":"Kassay","year":"2021","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.nmni.2026.101776_bib17","first-page":"19","article-title":"Design of new potent HTLV-1 protease inhibitors: in silico study","volume":"5","author":"Kheirabadi","year":"2016","journal-title":"Mol Biol Res Commun"},{"issue":"12","key":"10.1016\/j.nmni.2026.101776_bib18","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.1021\/acs.jcim.3c00440","article-title":"Catalytic mechanism of human T-Cell leukemia virus type 1 protease investigated by combined QM\/MM molecular dynamics simulations","volume":"63","author":"Petrillo","year":"2023","journal-title":"J Chem Inf Model"},{"issue":"3","key":"10.1016\/j.nmni.2026.101776_bib19","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1042\/BJ20071132","article-title":"C-terminal residues of mature human T-lymphotropic virus type 1 protease are critical for dimerization and catalytic activity","volume":"416","author":"Kadas","year":"2008","journal-title":"Biochem J"},{"key":"10.1016\/j.nmni.2026.101776_bib20","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/bs.enz.2021.09.004","article-title":"Viral proteases: structure, mechanism and inhibition","volume":"50","author":"Zephyr","year":"2021","journal-title":"Enzymes"},{"issue":"5","key":"10.1016\/j.nmni.2026.101776_bib21","doi-asserted-by":"crossref","first-page":"883","DOI":"10.3851\/IMP2090","article-title":"Kinetic characterization of newly discovered inhibitors of various constructs of human T-cell leukemia virus-1 (HTLV-1) protease and their effect on HTLV-1-infected cells","volume":"17","author":"Demir","year":"2012","journal-title":"Antivir Ther"},{"issue":"4","key":"10.1016\/j.nmni.2026.101776_bib22","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/0966-842X(93)90127-D","article-title":"HTLV-1 tax: regulation of gene expression and disease","volume":"1","author":"Yoshida","year":"1993","journal-title":"Trends Microbiol"},{"issue":"3","key":"10.1016\/j.nmni.2026.101776_bib23","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20211921","article-title":"Regulation of HTLV-1 transformation","volume":"42","author":"Ernzen","year":"2022","journal-title":"Biosci Rep"},{"issue":"18","key":"10.1016\/j.nmni.2026.101776_bib24","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1182\/blood-2010-11-316463","article-title":"Kinetics and intracellular compartmentalization of HTLV-1 gene expression: nuclear retention of HBZ mRNAs","volume":"117","author":"Rende","year":"2011","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.nmni.2026.101776_bib25","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1182\/blood-2010-06-293340","article-title":"Suppression of HTLV-1 replication by tax-mediated rerouting of the p13 viral protein to nuclear speckles","volume":"118","author":"Andresen","year":"2011","journal-title":"Blood"},{"issue":"1\u20132","key":"10.1016\/j.nmni.2026.101776_bib26","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s10989-006-9062-z","article-title":"Studies on substrate specificity at PR\/p3 cleavage site of HTLV-1 protease","volume":"13","author":"Bang","year":"2007","journal-title":"Int J Pept Res Therapeut"},{"issue":"20","key":"10.1016\/j.nmni.2026.101776_bib27","doi-asserted-by":"crossref","first-page":"6287","DOI":"10.1046\/j.1432-1327.2000.01714.x","article-title":"Comparison of the substrate specificity of the human T-cell leukemia virus and human immunodeficiency virus proteinases","volume":"267","author":"Tozser","year":"2000","journal-title":"Eur J Biochem"},{"issue":"5","key":"10.1016\/j.nmni.2026.101776_bib28","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1158\/2643-3230.BCD-21-0044","article-title":"Single-cell analysis of the multicellular ecosystem in viral carcinogenesis by HTLV-1","volume":"2","author":"Koya","year":"2021","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"10.1016\/j.nmni.2026.101776_bib29","doi-asserted-by":"crossref","first-page":"2693","DOI":"10.1007\/s00894-011-0971-1","article-title":"A comparative study of HIV-1 and HTLV-I protease structure and dynamics reveals a conserved residue interaction network","volume":"17","author":"Rucker","year":"2011","journal-title":"J Mol Model"},{"issue":"2","key":"10.1016\/j.nmni.2026.101776_bib30","doi-asserted-by":"crossref","first-page":"31","DOI":"10.21859\/isv.10.2.3.31","article-title":"The comparative analysis of the protease molecule structure of the human lymphotropic virus type-1 (HTLV-1)","volume":"10","author":"Habibi","year":"2016","journal-title":"Iranian Journal of Virology"},{"issue":"11","key":"10.1016\/j.nmni.2026.101776_bib31","doi-asserted-by":"crossref","first-page":"4845","DOI":"10.1021\/acs.jmedchem.5b00346","article-title":"Privileged structures meet human T-Cell leukemia Virus-1 (HTLV-1): C2-symmetric 3,4-Disubstituted pyrrolidines as nonpeptidic HTLV-1 protease inhibitors","volume":"58","author":"Kuhnert","year":"2015","journal-title":"J Med Chem"},{"key":"10.1016\/j.nmni.2026.101776_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiolchem.2021.107616","article-title":"Reconstruction of the binding pathway of an anti-HIV drug, indinavir, in complex with the HTLV-1 protease using unaggregated unbiased molecular dynamics simulation","volume":"96","author":"Sohraby","year":"2022","journal-title":"Comput Biol Chem"},{"issue":"5","key":"10.1016\/j.nmni.2026.101776_bib33","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/10799893.2014.898659","article-title":"Molecular modeling studies and comparative analysis on structurally similar HTLV and HIV protease using HIV-PR inhibitors","volume":"34","author":"Selvaraj","year":"2014","journal-title":"J Recept Signal Transduct Res"},{"issue":"Pt 7","key":"10.1016\/j.nmni.2026.101776_bib34","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1099\/vir.0.82704-0","article-title":"Bovine leukemia virus protease: comparison with human T-lymphotropic virus and human immunodeficiency virus proteases","volume":"88","author":"Sperka","year":"2007","journal-title":"J Gen Virol"},{"issue":"4","key":"10.1016\/j.nmni.2026.101776_bib35","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.jmb.2010.06.052","article-title":"Crystal structures of inhibitor complexes of human T-cell leukemia virus (HTLV-1) protease","volume":"401","author":"Satoh","year":"2010","journal-title":"J Mol Biol"},{"issue":"1","key":"10.1016\/j.nmni.2026.101776_bib36","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.bmcl.2007.10.066","article-title":"Truncation and non-natural amino acid substitution studies on HTLV-I protease hexapeptidic inhibitors","volume":"18","author":"Nguyen","year":"2008","journal-title":"Bioorg Med Chem Lett"},{"issue":"11","key":"10.1016\/j.nmni.2026.101776_bib37","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1080\/07391102.2022.2078411","article-title":"Repurposing antiviral drugs against HTLV-1 protease by molecular docking and molecular dynamics simulation","volume":"41","author":"Jahantigh","year":"2023","journal-title":"J Biomol Struct Dyn"},{"issue":"11","key":"10.1016\/j.nmni.2026.101776_bib38","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.3390\/ph16111546","article-title":"New perspectives about drug candidates targeting HTLV-1 and related diseases","volume":"16","author":"Silva","year":"2023","journal-title":"Pharmaceuticals"},{"issue":"2","key":"10.1016\/j.nmni.2026.101776_bib39","doi-asserted-by":"crossref","DOI":"10.5812\/ijhls.89840","article-title":"The design of novel Kni-10729 based compound for inhibition of HTLV-1 protease as novel insight for development of Anti-HTLV drugs","volume":"5","author":"Keikha","year":"2019","journal-title":"International Journal of Health and Life Sciences"},{"key":"10.1016\/j.nmni.2026.101776_bib40","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.881547","article-title":"HTLV-1 transmission and HIV pre-exposure prophylaxis: a scoping review","volume":"9","author":"Bradshaw","year":"2022","journal-title":"Front Med"},{"issue":"5","key":"10.1016\/j.nmni.2026.101776_bib41","doi-asserted-by":"crossref","first-page":"342","DOI":"10.3390\/pathogens9050342","article-title":"Antiretroviral therapy in HTLV-1 infection: an updated overview","volume":"9","author":"Marino-Merlo","year":"2020","journal-title":"Pathogens"},{"issue":"4","key":"10.1016\/j.nmni.2026.101776_bib42","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1002\/bip.22780","article-title":"New directions for protease inhibitors directed drug discovery","volume":"106","author":"Hamada","year":"2016","journal-title":"Biopolymers"},{"key":"10.1016\/j.nmni.2026.101776_bib43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1080\/14737175.2023.2272639","article-title":"Advances in the treatment of human T-cell lymphotropic virus type-I associated myelopathy","volume":"23","author":"Mashkani","year":"2023","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"10.1016\/j.nmni.2026.101776_bib44","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1515\/BC.2004.134","article-title":"Design of inhibitors against HIV, HTLV-I, and Plasmodium falciparum aspartic proteases","volume":"385","author":"Abdel-Rahman","year":"2004","journal-title":"Biol Chem"},{"issue":"10","key":"10.1016\/j.nmni.2026.101776_bib45","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.3390\/v16101616","article-title":"Current state of therapeutics for HTLV-1","volume":"16","author":"Wang","year":"2024","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.nmni.2026.101776_bib46","doi-asserted-by":"crossref","DOI":"10.3390\/v18010140","article-title":"The differentially regulated cousins: insights into the differences in transcriptional regulatory mechanisms between HTLV-1 and HIV-1","volume":"18","author":"Reda","year":"2026","journal-title":"Viruses"},{"key":"10.1016\/j.nmni.2026.101776_bib47","doi-asserted-by":"crossref","first-page":"278","DOI":"10.3389\/fmicb.2018.00278","article-title":"How to Control HTLV-1-Associated Diseases: preventing de Novo Cellular Infection Using Antiviral Therapy","volume":"9","author":"Pasquier","year":"2018","journal-title":"Front Microbiol"},{"issue":"1","key":"10.1016\/j.nmni.2026.101776_bib48","doi-asserted-by":"crossref","first-page":"5720","DOI":"10.1038\/s41467-025-61279-y","article-title":"Machine learning-assisted decoding of temporal transcriptional dynamics via fluorescent timer","volume":"16","author":"Irie","year":"2025","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.nmni.2026.101776_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241914807","article-title":"Human T-Cell leukemia virus type 1 oncogenesis between active expression and latency: a possible source for the development of therapeutic targets","volume":"24","author":"Marino-Merlo","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"11","key":"10.1016\/j.nmni.2026.101776_bib50","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115545","article-title":"Latency reversing agents: Kick and kill of HTLV-1?","volume":"22","author":"Schnell","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.nmni.2026.101776_bib51","doi-asserted-by":"crossref","first-page":"137","DOI":"10.2174\/187152409788452090","article-title":"Therapeutic strategies in HTLV-I-associated myelopathy\/tropical spastic paraparesis (HAM\/TSP)","volume":"9","author":"Nakamura","year":"2009","journal-title":"Cent Nerv Syst Agents Med Chem"},{"issue":"3","key":"10.1016\/j.nmni.2026.101776_bib52","doi-asserted-by":"crossref","first-page":"407","DOI":"10.3390\/pharmaceutics16030407","article-title":"Nanomedicine for the treatment of viral diseases: smaller solution to bigger problems","volume":"16","author":"Ghorai","year":"2024","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.nmni.2026.101776_bib53","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/ijms22063232","article-title":"Mechanisms of proteolytic enzymes and their inhibition in QM\/MM studies","volume":"22","author":"Els\u00e4sser","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"1732","key":"10.1016\/j.nmni.2026.101776_bib54","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2016.0272","article-title":"Human T-cell leukaemia virus type 1: parasitism and pathogenesis","volume":"372","author":"Bangham","year":"2017","journal-title":"Philos Trans R Soc Lond B Biol Sci"},{"issue":"6","key":"10.1016\/j.nmni.2026.101776_bib55","article-title":"HTLV-1 oncovirus-host interactions: from entry to the manifestation of associated diseases","volume":"31","author":"Ahmadi","year":"2021","journal-title":"Rev Med Virol"},{"key":"10.1016\/j.nmni.2026.101776_bib56","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1586\/1744666X.2014.966690","article-title":"Inflammatory manifestations of HTLV-1 and their therapeutic options","volume":"10","author":"Martin","year":"2014","journal-title":"Expert Rev Clin Immunol"}],"container-title":["New Microbes and New Infections"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297526000806?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2052297526000806?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:12:59Z","timestamp":1785226379000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2052297526000806"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":56,"alternative-id":["S2052297526000806"],"URL":"https:\/\/doi.org\/10.1016\/j.nmni.2026.101776","relation":{},"ISSN":["2052-2975"],"issn-type":[{"value":"2052-2975","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The challenge of HTLV-1 therapeutics: lessons from anti-protease approaches","name":"articletitle","label":"Article Title"},{"value":"New Microbes and New Infections","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nmni.2026.101776","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101776"}}